A humanoid robot being escorted away by police in Macau has gone viral online, prompting jokes about what some called the world’s first “robot arrest.”
Updated
March 17, 2026 12:53 AM
Macau police officer accompanying the humanoid robot. PHOTO: THREADS@BOXOF_CHOCOLATE
Police in Macau recently detained a humanoid robot after it frightened an elderly woman on a public street. The unusual encounter quickly spread online, prompting jokes about what some called the world’s first “robot arrest”.
On the evening of March 5, the robot was taken away by officers after the encounter triggered alarm among bystanders. Videos circulating on social media show an elderly woman confronting the robot on a sidewalk, visibly distressed and shouting that her “heart is pounding” while demanding to know why such “nonsense” was happening on the street. In the clip, the robot raises both hands toward the woman after she lashes out in fear — a gesture many viewers interpreted as a sign of apology.
Shortly afterwards, two officers from the Macau Public Security Police Force were seen escorting the robot and a man believed to be its operator away from the area. An officer is seen placing his right hand on the robot’s shoulder — the same posture police often use when presenting arrested suspects in official photographs.
That scene quickly spread online, fuelling jokes about what some called the world’s first “robot arrest”.
Photos shared online show a humanoid robot with long limbs and exposed mechanical joints, built from a black metallic frame without an outer shell. In dim lighting, several commenters said it resembled a “moving skeleton” — a striking sight for pedestrians encountering it unexpectedly on the street.
Witnesses said the woman appeared severely shaken and an ambulance was eventually called to take her to the hospital.
The incident also sparked discussion online about robots operating in public spaces. Some commenters argued that experimental technologies should be tested in controlled environments, while others said machines moving through public areas should have clearer designs or safety measures to avoid alarming pedestrians.
It remains unclear who deployed the robot or what purpose it was serving in the area at the time of the incident. Authorities have not released further details about the device or whether any action was taken following the encounter.
Keep Reading
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.